GlassScriptPhysician profile
Elizabeth J Willens
NPI 1649965633
$2,355.70
in general payments reported to CMS, 2019-2025
16 companies · $790 in 2025
The $790 reported for 2025 was more than what 76% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $699 · 2024: $866 · 2025: $790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,348 · Education: $7.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,348.18 |
| Education | $7.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $716.19 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $408.75 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $298.36 | 2023-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $145.50 | 2023-2025 | Aristada, Lybalvi, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $135.09 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Lundbeck LLC | $124.23 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $95.68 | 2024-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $94.13 | 2024-2025 | Cobenfy |
| Bausch Health US, LLC | $81.58 | 2023-2025 | Aplenzin |
| Neos Therapeutics, LP | $75.09 | 2023-2024 | Adzenys Xr-Odt |
| Vanda Pharmaceuticals INC. | $61.20 | 2024-2025 | Hetlioz, Fanapt |
| Almatica Pharma LLC | $39.05 | 2024-2025 | Loreev Xr |
| Neurocrine Biosciences, INC. | $25.25 | 2025 | |
| Corium, LLC | $21.87 | 2023 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.04 | 2025 | Caplyta |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $15.69 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Willens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.